IDEAS home Printed from https://ideas.repec.org/a/spr/patien/v12y2019i6d10.1007_s40271-019-00378-7.html
   My bibliography  Save this article

What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism

Author

Listed:
  • T. Joseph Mattingly

    () (University of Maryland School of Pharmacy)

  • Julia F. Slejko

    (University of Maryland School of Pharmacy)

  • Eleanor M. Perfetto

    (University of Maryland School of Pharmacy
    National Health Council)

  • Shyamasundaran Kottilil

    (University of Maryland School of Medicine)

  • C. Daniel Mullins

    (University of Maryland School of Pharmacy)

Abstract

Abstract Objective Comparative evaluations of innovations in hepatitis C virus (HCV) drug therapy typically focus on sustained virologic response (SVR) without addressing psychological and socioeconomic challenges that extend beyond virologic cure. This study aims to identify and prioritize variables important to patients when making the decision to start HCV treatment. Methods A three-round Delphi process was conducted with the first round derived from a systematic literature review and advisory board input, including patients who have been affected by HCV, physicians, pharmacists, and a patient group representative. Delphi panelists were HCV patients who had received treatment or were considering treatment. Panelists were asked about factors influencing their HCV treatment decisions. Thematic analysis of open-ended responses based on grounded theory was used. Agreement with each category and rankings based on order of importance from the patient perspective was reported. Results Treatment effectiveness (100% agreement), longer life (88%), fear of complications (84%), financial issues (80%), quality of life (100%), and impact on society (80%) were considered important factors to patients in decisions to seek treatment. A fear of harming others (87%) was considered more important than physical symptoms (83%) in terms of patient-reported problems caused by HCV. Medication costs (91%) were identified as the most important costs of having HCV, followed by doctor costs (77%). Conclusions In addition to treatment effectiveness, patient experiences with financial problems, quality of life, and altruistic desires impact HCV patients’ decisions. The risk of infecting others may motivate patients to seek treatment as much as personally experienced physical symptoms.

Suggested Citation

  • T. Joseph Mattingly & Julia F. Slejko & Eleanor M. Perfetto & Shyamasundaran Kottilil & C. Daniel Mullins, 2019. "What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(6), pages 631-638, December.
  • Handle: RePEc:spr:patien:v:12:y:2019:i:6:d:10.1007_s40271-019-00378-7
    DOI: 10.1007/s40271-019-00378-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40271-019-00378-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Rita Faria’s journal round-up for 30th December 2019
      by Rita Faria in The Academic Health Economists' Blog on 2019-12-30 12:00:00

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:patien:v:12:y:2019:i:6:d:10.1007_s40271-019-00378-7. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla) or (Springer Nature Abstracting and Indexing). General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.